Mikhail Blagosklonny is a renowned scientist who has been internationally recognized due to his outstanding contributions towards aging and cancer research. The New York-based oncology professor has been serving Rosewell Park Cancer Institute since 2009 and has assisted it in conducting significant research on cancer treatment therapies. Blagosklonny has also written and published research content that shades light on aging and cancer. He believes in Rapamycin as an excellent cancer treatment that can be used in lengthening the lives of cancer patients. Mikhail has made significant achievements in his career for the past two decades.Rapamycin is a drug that has been used in curing different life-threatening conditions. It is also referred to as Sirolimus and was developed to prevent rejects that occur during organ transplants. The drug has been used in healing facial angiofibromas, hemolytic-uremic syndrome, tuberous sclerosis complex (TSC), lymphangioleiomyomatosis (LAM), and coating coronary stents. The cure’s current trade name is Rapamune, and it is used for cancer treatment in the pharmaceutical world.
Rapamycin was invented in 1972 from an individual bacteria sample that was acquired from EasternIsland. Scientists initially used it in curing fungal infections before they recognized its antiproliferative and immunosuppressive abilities.Blagosklonny’s research work is dedicated to offering targeted cancer treatments that can be used in saving the lives of the patients. The scientist’s work in the medical research sector has focused on cancer treatment and aging. He believes that the two fields are connected since most people who have cancer are beyond a certain age. Mikhail has committed himself to making discoveries that will help in improving the oncology world. He has made significant accomplishments as a professor and has been a role model to his students and peers.The oncology expert is a graduate of the First Pavlov State Medical University of St. Peterburg where he got his Ph.D. in cardiology and experimental medicine. Before that, Mikhail has pursued a master’s degree in internal medicine from the institution.
In 2002, the scientist was offered a job by the New York Medical College, which is based in Valhalla. He then moved to serve Ordway Research Institute where he acted as a senior scientist.In 2009, Blagosklonny joined the Roswell Park Cancer Institute, and he has been serving it as a professor of oncology. He has done outstanding research that has helped in the development of targeted cancer therapies that protect healthy body cells. The scientist has also studied a lot about the aging mechanism and anti-aging treatments. Mikhail has developed a concept that seeks to explain how TOR signaling can affect cancer and aging. He has advised medical experts to use Rapamycin since it is a reliable cancer cure.Mikhail Blagosklonny is also recognized because of his work as an editor. He has served as an editor-in-chief in oncology, aging, cell cycle, and oncotarget. The scientist has also been a therapy and cancer biology associate editor. His expertise has enabled him to sit on the editorial board of the cell differentiation and death. He has written several research papers, articles, and book chapters.